Pennisi Angela, Kieber-Emmons Thomas, Makhoul Issam, Hutchins Laura
Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Breast Cancer (Auckl). 2016 Jul 25;10:103-6. doi: 10.4137/BCBCR.S33163. eCollection 2016.
Breast cancer is a heterogeneous disease, and the different biological subtypes have different prognostic impacts. Neoadjuvant trials have recently become popular as they offer several advantages compared to traditional adjuvant trials. Studies have shown that patients who achieve pathological complete response (pCR) after neoadjuvant treatment have a better long-term outcome. Consequently, increasing the rate of pCR became the end point of neoadjuvant trials with the expectation of translation into improved survival. However, the definition of pCR has lacked uniformity, and the prognostic impact of achievement of pCR on survival in different breast cancer subtypes is uncertain. In this review, we present the controversies associated with the use of pCR as an end point in neoadjuvant trials.
乳腺癌是一种异质性疾病，不同的生物学亚型具有不同的预后影响。新辅助试验近来颇受青睐，因为与传统辅助试验相比，它们具有若干优势。研究表明，新辅助治疗后达到病理完全缓解（pCR）的患者具有更好的长期预后。因此，提高pCR率成为新辅助试验的终点，期望借此改善生存情况。然而，pCR的定义缺乏一致性，且在不同乳腺癌亚型中达到pCR对生存的预后影响尚不确定。在本综述中，我们阐述了与将pCR用作新辅助试验终点相关的争议。
